Peptide Atlas · Peptide

IGF-1 LR3

LONG R3IGF-I is an analogue of IGF-I engineered for biopharmaceutical protein production in mammalian cells, supporting growth and survival in serum-free media at concentrations at least 200-fold lower than insulin.

preclinical

provisional
2 citations
0 discussions
0 followers
LR3-IGF-1
Long Arg3 IGF-1
Long R3 IGF-1
LongR3 IGF-I

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

preclinical — animal, cell or mechanistic work — not yet about people

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for IGF-1 LR3. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
LONG R3IGF-I as a potent alternative to insulin in serum-free cell culture	preclinical	pmid 17172665
Plasma clearance and tissue distribution of LR3IGF-I in rats	preclinical	pmid 7693845

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.